Irvine, United States
Amberstone Biosciences is an innovative biotechnology company founded in 2018 and based in Irvine, California. Specializing in the healthcare sector, Amberstone's mission is articulated through its slogan: Developing Next-generation Tumor Microenvironment Activated Therapeutics.
The company is advancing its portfolio using its proprietary T-MATE platform, which tailors T cell engagers (TCEs) to combat solid tumors. By activating these therapeutics specifically in the acidic environments typical of tumor microenvironments, the platform minimizes on-target toxicity, offering safer, more effective treatment options than conventional TCEs.
In January 2022, Amberstone received a $12.00M Series A investment to push forward this promising tech. This funding round was backed by a diverse group of investors, including Viva BioInnovator, Cowin Venture, Sinovation Ventures, Xiamen Changrong Investment Management, and Lifespan Investments.
